OXBDF / Oxford Biomedica Plc (OXBDF) Interim CEO Dr. Roch Doliveux on Q4 2021 Results - Earnings Call Transcript

Oxford Biomedica jumped 10% as it started exclusive negotiations to acquire ABL Europe, a contract manufacturing (CDMO) business, from Institut Mérie more_horizontal

Oxford Biomedica's shares jumped as much as 16% on Wednesday after the British cell and gene therapy company said it would break even earlier than exp more_horizontal

Britain's Oxford Biomedica announced an agreement to potentially make AstraZeneca's COVID-19 vaccine beyond 2022. It has already manufactured more tha more_horizontal

Oxford Biomedica Plc ( OTCPK:OXBDF ) Q4 2021 Earnings Conference Call April 20, 2022 8:00 AM ET Company Participants Dr. Roch Doliveux – Chairman, I more_horizontal

London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc more_horizontal

London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc more_horizontal

London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc more_horizontal

Oxford Biomedica PLC announced an agreement with US company Homology Medicines Inc. to form an adeno-associated virus (AAV)-focused manufacturing and more_horizontal